Sergio Bracarda
Azienda Usl 8 Arezzo, Ospedale San Donato, Santa Maria Nuova Hospital
Papers
3
Total Citations
56
H-Index
3
About
Sergio Bracarda is a leading figure in genitourinary oncology, with a primary focus on prostate cancer treatment and outcomes. His research bridges the gap between surgical innovation and patient quality of life, particularly through large-scale, real-world evidence. As a key investigator in the multicenter Pros-IT CNR study, Bracarda has advanced the understanding of how surgical approaches—such as radical prostatectomy—affect patient-reported outcomes. His 2019 propensity score-weighted analysis of this study (28 citations) demonstrated that surgical technique significantly impacts post-operative health-related quality of life, offering critical guidance for shared decision-making. Additionally, Bracarda contributed to the final pooled analysis of cabazitaxel in metastatic castration-resistant prostate cancer (25 citations), providing robust real-world data on the efficacy and safety of this chemotherapy in compassionate use and early access programs. His work on the MIRROR-SIU/LUNA and Pros-IT CNR studies has also documented the evolution of surgical practices in Italy over a decade. With a career dedicated to translating clinical data into tangible improvements in patient care, Bracarda’s research is essential reading for clinicians and researchers seeking evidence-based strategies in prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3